IPF is associated with high healthcare costs due to increased utilization and comorbidities, despite its rarity. Nintedanib and pirfenidone show promise in slowing IPF progression but are costly, ...
Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results